• 1
    Ward HP, Block MH. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine (Baltimore) 1971;50:357420.
  • 2
    Tefferi A. Myelofibrosis with myeloid metaplasia N Engl J Med 2000;342(17):12551265.
  • 3
    Hasselbalch HC. Idiopathic myelofibrosis. Am J Hematol 1990;34:291300.
  • 4
    Cervantes F, Pereira A, Esteve J, et al. Identification of “short-lived” and “long-lived” patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997;97:635640.
  • 5
    Thiele J, Zankovich R, Steinberg T, Kremer B, Fischer R, Diehl V. Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis. A critical evaluation of clinical and histomorphological data. Acta Haematol 1989;81:192202.
  • 6
    Thiele J, Kvasnicka HM, Werden C, Zankovich R, Diehl V, Fischer R. Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuk Lymphoma 1996;22:303317.
  • 7
    Thiele J, Kvasnicka HM, Fischer R, Diehl V. Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: a concise update. Leuk Lymphoma 1997;24:463481.
  • 8
    Castro-Malaspina H. Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components. In: BerkPD, Castro-MalaspinaH, WassermanLR, editors. Myelofibrosis and the biology of connective tissue. New York: Alan R. Liss, Inc.; 1984. pp. 427454.
  • 9
    Martyre MC, Magdelenat H, Bryckaert H, Laine-Bidron C, Calvo F. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-b in patients with myelofibrosis with myeloid, metaplasia. Br J Haematol 1991;77:8086.
  • 10
    Martyre MC, Romquin N, Le Bousse-Kerdiles MC, et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994;88:916.
  • 11
    Le Bousse-Kerdiles M-C, Chevillard S, Charpentier A, et al. Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 1996;88(12):45344546.
  • 12
    Martyre MC, Le Bousse-Kerdiles MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 1997;97:441448.
  • 13
    Le Bousse-Kerdiles MC, Martyre MC. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol 1999;78:437444.
  • 14
    Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100104.
  • 15
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:10311037.
  • 16
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:10381042.
  • 17
    Beham-Schmid C, Apfelbeck U, Sill H, et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 2002;99:381383.
  • 18
    Tefferi A, Mesa RA, Gray LA, et al. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood 2002;99:38543856.
  • 19
    Gisslinger H, Gisslinger B, Kees M, et al. Imatinib mesylate in chronic idiopathic myelofibrosis, a phase II trial. Blood 2002;100:800a. abstract # 3161.
  • 20
    Paggio G, Castello S, Podesta M, et al. Low number of circulating CD34+ cells identifies a group of patients with myelofibrosis with myeloid metaplasia (MMM) who efficiently responds to STI571. Blood 2001;98:Abstract # 2630.
  • 21
    Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34 (+) cells in myelofibrosis with myeloid metaplasia. Blood 2001;98(12):32493255.
  • 22
    Kano Y, Akutsu M, Tsunoda S, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001;97:19992007.
  • 23
    Canepa L, Ballerini F, Varaldo R, et al. Thalidomide in agnogenic and secondary myelofibrosis. Br J Haematol 2001;115:313315.
  • 24
    Elliot MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002;117:288296.